- Home
- STG vs QNCX Comparison
STG vs QNCX Comparison
Compare STG & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STG | QNCX |
|---|---|---|
| Founded | 2003 | 2012 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 112.4M | 139.2M |
| IPO Year | 2018 | 2019 |
Fundamental Metrics
Financial Performance| Metric | STG | QNCX |
|---|---|---|
| Price | $6.40 | $3.56 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 5.4K | ★ 943.8K |
| Earning Date | 11-20-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.01 | N/A |
| Revenue | ★ $285,589,112.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.60 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.28 | $0.72 |
| 52 Week High | $15.00 | $4.55 |
Technical Indicators
Market Signals| Indicator | STG | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 56.84 | 55.80 |
| Support Level | $5.49 | $3.44 |
| Resistance Level | $6.48 | $3.80 |
| Average True Range (ATR) | 0.33 | 0.34 |
| MACD | 0.12 | -0.10 |
| Stochastic Oscillator | 86.67 | 17.77 |
Price Performance
Historical ComparisonAbout STG Sunlands Technology Group
Sunlands Technology Group is a provider of online post-secondary and professional education services in China. The company offers various degree- and diploma-oriented post-secondary courses through its online platforms. In addition, it provides online professional courses and educational content to help students prepare for professional certification exams and attain professional skills. The Group has one operating segment, which is the provision of online education services.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.